+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors



Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors



Zhonghua Wai Ke Za Zhi 51(3): 256-260



To investigate the oncologic outcomes of surveillance, retroperitoneal lymph node dissection (RPLND) and primary chemotherapy in patients with clinical stage Ia nonseminomatous germ cell testicular tumors (CS Ia NSGCT) and to analyze risk factors for relapse. Patients with CS Ia NSGCT were retrospectively reviewed. Totally 72 patients were enrolled and grouped according to three different treatment after orchiectomy, among them 33 cases in surveillance group, 24 cases in RPLND group and 15 cases in primary chemotherapy group. Disease progressive free survival and disease specific survival were compared using Kaplan-Meier analysis. Cox regression analysis was used to confirm variables those were associated with disease progression. All 72 patients were followed-up at mean 62 months (12 - 175 months), 6 patients had evidence of relapse. Both the 5-year disease specific survival and 5-year overall survival rate were 100%. For surveillance, chemotherapy and RPLND, cumulative 5-year PFS rates were 84.0%, 93.3% and 100%, respectively. Relapse rate was higher in surveillance group than in RPLND group (17.8% vs. 0, χ² = 3.99, P = 0.04). Patients with the history of cryptorchidism also have higher relapse rate than without (37.5% vs. 4.7%, χ² = 10.02, P = 0.01). In the surveillance cohort, relapse rates were significantly higher in patients with a predominant component of embryonal carcinoma (3/6 vs. 7.4%, χ² = 6.93, P = 0.04) and for those over 13 years of age (23.1% vs. 5.3%, χ² = 4.33, P = 0.04). On multivariate analysis, treatment mode of patients (OR = 0.08, 95% CI: 0.06-0.36, P = 0.03) and patients with a history of cryptorchidism (OR = 25.3, 95% CI: 6.57-78.42, P = 0.04) were independent predictors of relapse. Surveillance, RPLND and adjuvant chemotherapy could be reliable strategies in compliant stage Ia nonseminoma patients and achieve satisfactory overall survival. Relapse rate is relatively higher for patients with surveillance. Those who are older or have a history of cryptorchidism experience a higher risk of relapse.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052894563

Download citation: RISBibTeXText

PMID: 23859330


Related references

Nonseminomatous germ cell testicular tumors clinical stage I A retrospective analysis. EJC Suppl.s 1(5): S271, 2003

Automated image analysis DNA cytometry to predict the pathological stage in clinical stage I nonseminomatous testicular germ cell tumors. European Urology 31(3): 356-359, 1997

Nonseminomatous germ cell testicular tumors - clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance. Neoplasma 54(5): 437-442, 2007

Therapeutic approaches for early stage nonseminomatous germ cell testicular tumors. Klinicka Onkologie 21(3): 81-85, 2008

New prognostic parameters to predict pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. Journal of Urology 153(4 Suppl. ): 244A, 1995

Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. Journal of Urology 155(2): 579-586, 1996

Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World Journal of Urology 33(9): 1351-1357, 2015

Clinical evaluation of surgical stage I and IIA nonseminomatous testicular germ cell tumors. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 78(6): 1060-1064, 1987

Cytogenetic abnormalities and clinical stage in testicular nonseminomatous germ cell tumors. Cancer Genetics & Cytogenetics. 70(1): 12-16, 1993

Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Journal of Clinical Oncology 21(8): 1505-1512, 2003

Surveillance study for clinical stage I testicular seminomas and nonseminomatous germ cell tumors. International Journal of Urology 5(6): 568-574, 1998

Comparison between clinical and pathological staging in low stage nonseminomatous germ cell testicular tumors. Journal of Urology 148(1): 76-79, 1992

The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. Seminars in Urology 11(2): 92-98, 1993

Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. Journal of Clinical Oncology 8(3): 509-518, 1990

DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I. Cancer 67(7): 1874-1877, 1991